Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis

Phase 2 Completed 43 enrolled River 3 Renal Corp.

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a Phase 2, Multi-center, Open-Label Study to Assess Safety, Tolerability, Efficacy and Pharmacokinetics of R3R01 in Alport Syndrome Patients with Uncontrolled Proteinuria on ACE/ARB Inhibition and in Patients with Primary Steroid-Resistant Focal Segmental Glomerulosclerosis

Timeline

Start: 2022-06-15
Primary completion: 2025-05-21
Completion: 2025-08-19

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	R3R01	Small molecule	200 mg	Oral

Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis

Summary

Timeline

Drugs

Indications